Evidence-led education. Independently researched. Medically reviewed content clearly labeled.
Live Wellness

Medication comparison

Wegovy vs Zepbound: Evidence, Dosing & Safety Compared

Compare Wegovy and Zepbound by labeled use, mechanism, titration, direct head-to-head evidence, safety, and practical prescribing questions.

Updated September 14, 2026 16 min read

The short answer

Wegovy and Zepbound are both labeled for chronic weight management, but they use different ingredients, receptor mechanisms, formulations, dose ladders, and additional indications. A direct 72-week obesity trial favored tirzepatide for average weight reduction in its studied population; that result does not make Zepbound a universal winner or apply to every formulation, diagnosis, or person.

Wegovy vs Zepbound at a glance

The biggest difference is semaglutide glp-1 activity versus tirzepatide dual gip/glp-1 activity, with different labels and evidence. Milligram amounts across different active ingredients are not equivalent.

Comparison table for Wegovy and Zepbound
FeatureWegovyZepbound
Active ingredientSemaglutideTirzepatide[1,2]
Receptor activityGLP-1 receptor agonistGIP and GLP-1 receptor agonist[1,2]
Weight-management populationDefined adults; adolescents age 12+ with obesityDefined adults[1,2]
Additional labeled usesCardiovascular risk reduction in defined adults; noncirrhotic MASH with F2–F3 fibrosis in adultsModerate-to-severe obstructive sleep apnea in adults with obesity[1,2]
Current formulationsWeekly injection and daily tablet, with indication-specific instructionsWeekly injection[1,2]
Injection initiation0.25 mg weekly for weeks 1–42.5 mg weekly for 4 weeks; not a maintenance dose[1,2]
Injection maintenance for weight management1.7 mg or 2.4 mg weekly5 mg, 10 mg, or 15 mg weekly[1,2]
Direct obesity comparison13.7% mean loss at week 7220.2% mean loss at week 72[3]
Direct-trial scopeMaximum tolerated weekly injection, 1.7 or 2.4 mgMaximum tolerated weekly injection, 10 or 15 mg[3]

What the evidence can—and cannot—compare

Direct head-to-head evidence

SURMOUNT-5 randomly assigned 751 adults with obesity but without diabetes to maximum tolerated weekly tirzepatide or semaglutide injection. At week 72, mean weight change was −20.2% with tirzepatide and −13.7% with semaglutide. Gastrointestinal events were the most common adverse events in both groups and were usually mild to moderate during escalation.[3]

What that direct result does not establish

The trial does not compare every patient, indication, dose, insurance pathway, or Wegovy’s oral formulation. It also does not show that one medicine is safer or more appropriate for every person. The open-label design and industry funding belong in the interpretation.[3]

Why separate placebo trials remain indirect

STEP 1 reported a 14.9% mean weight reduction at 68 weeks with semaglutide 2.4 mg plus lifestyle intervention. SURMOUNT-1 reported mean reductions of 15.0%, 19.5%, and 20.9% at 72 weeks with tirzepatide 5, 10, and 15 mg. Those trials differed in design and populations; placing their numbers beside each other is not a randomized comparison.[4,5]

Safety differences begin with the exact label

Both labels contain boxed thyroid C-cell tumor warnings and describe pancreatitis, gallbladder disease, kidney injury related to volume depletion, severe gastrointestinal reactions, hypersensitivity, hypoglycemia with some diabetes medicines, and aspiration risk around anesthesia. Tirzepatide labeling also gives specific oral-contraceptive precautions after initiation and dose escalation; Wegovy labeling contains formulation- and population-specific considerations.[1,2]

A prescriber discussion checklist

Ask which labeled indication applies; whether weekly injection or another formulation is being considered; how titration will respond to symptoms; whether eye, kidney, gallbladder, pancreatic, pregnancy, contraception, diabetes-medication, or procedure history changes the plan; how benefit will be measured; and what happens if access is interrupted.[1,2]

May be best aligned with

Wegovy

A person whose indication, history, formulation preference, and access align with semaglutide

  • Includes adolescent weight-management labeling
  • Has specific cardiovascular risk-reduction and MASH indications
  • Current label includes injection and oral options with separate instructions

May be best aligned with

Zepbound

A person whose indication, history, dose plan, and access align with tirzepatide

  • Dual GIP/GLP-1 receptor activity
  • Has a specific obstructive-sleep-apnea indication
  • Produced greater mean weight reduction in the studied SURMOUNT-5 population

Consider these tradeoffs

  • SURMOUNT-5 was open-label, manufacturer-funded, and excluded people with diabetes
  • The direct trial compared weekly injections at maximum tolerated doses—not every dose or the Wegovy tablet
  • The labels differ beyond weight loss, so diagnosis can matter more than the group average
  • Tolerability, contraindications, pregnancy plans, other medicines, and reliable access can change the decision

Frequently asked questions

Did a trial directly compare Wegovy and Zepbound?

SURMOUNT-5 directly compared maximum tolerated weekly tirzepatide and semaglutide injections in adults with obesity without diabetes. It did not compare every dose, indication, or the Wegovy tablet.

Does the larger average make Zepbound best for everyone?

No. A group average cannot account for an individual’s indication, contraindications, adverse effects, other medicines, pregnancy plans, formulation preference, monitoring needs, or access.

Can Wegovy and Zepbound doses be converted directly?

No. They use different active ingredients and dose ladders. A switch and its timing require product-specific instructions from the prescriber.

Sources

  1. Wegovy prescribing information — U.S. Food and Drug Administration (2025-12)
  2. Zepbound prescribing information — U.S. Food and Drug Administration (2026-02)
  3. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity — New England Journal of Medicine (2025-05-11)
  4. Once-Weekly Semaglutide in Adults with Overweight or Obesity — New England Journal of Medicine (2021-02-10)
  5. Tirzepatide Once Weekly for the Treatment of Obesity — New England Journal of Medicine (2022-06-04)

Related guidance